Aldeyra The (ALDX) - Total Assets
Based on the latest financial reports, Aldeyra The (ALDX) holds total assets worth $77.80 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See ALDX net asset value for net asset value and shareholders' equity analysis.
Aldeyra The - Total Assets Trend (2011–2024)
This chart illustrates how Aldeyra The's total assets have evolved over time, based on quarterly financial data.
Aldeyra The - Asset Composition Analysis
Current Asset Composition (December 2024)
Aldeyra The's total assets of $77.80 Million consist of 99.5% current assets and 0.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 52.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Aldeyra The's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Aldeyra The (ALDX) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aldeyra The's current assets represent 99.5% of total assets in 2024, an increase from 98.6% in 2011.
- Cash Position: Cash and equivalents constituted 52.1% of total assets in 2024, down from 96.9% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Aldeyra The Competitors by Total Assets
Key competitors of Aldeyra The based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Aldeyra The - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.72 | 6.80 | 6.69 |
| Quick Ratio | 2.72 | 6.80 | 6.69 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $48.98 Million | $99.57 Million | $70.65 Million |
Aldeyra The - Advanced Valuation Insights
This section examines the relationship between Aldeyra The's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.76 |
| Latest Market Cap to Assets Ratio | 0.91 |
| Asset Growth Rate (YoY) | -29.5% |
| Total Assets | $104.61 Million |
| Market Capitalization | $95.66 Million USD |
Valuation Analysis
Near Book Valuation: The market values Aldeyra The's assets close to their book value (0.91x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Aldeyra The's assets decreased by 29.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Aldeyra The (2011–2024)
The table below shows the annual total assets of Aldeyra The from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $104.61 Million | -29.48% |
| 2023-12-31 | $148.33 Million | -18.18% |
| 2022-12-31 | $181.29 Million | -22.24% |
| 2021-12-31 | $233.14 Million | +179.70% |
| 2020-12-31 | $83.35 Million | +10.37% |
| 2019-12-31 | $75.52 Million | -20.58% |
| 2018-12-31 | $95.09 Million | +115.26% |
| 2017-12-31 | $44.17 Million | +75.38% |
| 2016-12-31 | $25.19 Million | -10.70% |
| 2015-12-31 | $28.20 Million | +220.98% |
| 2014-12-31 | $8.79 Million | +134.75% |
| 2013-12-31 | $3.74 Million | +89.34% |
| 2012-12-31 | $1.98 Million | +663.61% |
| 2011-12-31 | $258.90K | -- |
About Aldeyra The
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatm… Read more